John Edward A. Blair to Double-Blind Method
This is a "connection" page, showing publications John Edward A. Blair has written about Double-Blind Method.
Connection Strength
0.252
-
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011 Oct; 32(20):2563-72.
Score: 0.064
-
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008 Nov 11; 52(20):1640-8.
Score: 0.053
-
Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am J Ther. 2008 May-Jun; 15(3):231-40.
Score: 0.051
-
Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial. JAMA Cardiol. 2024 12 01; 9(12):1143-1153.
Score: 0.040
-
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown). 2012 Jul; 13(7):415-22.
Score: 0.017
-
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J. 2009 Sep; 158(3):437-43.
Score: 0.014
-
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009 Sep; 30(18):2233-40.
Score: 0.014